NASDAQ:SCPHScpharmaceuticals Stock Price, Forecast & News

$8.33

-0.04 (-0.48 %)

(As of 06/1/2020 04:00 PM ET)

Add

Compare

Today's Range

$8.00

Now: $8.33▼

$8.61

50-Day Range

$8.29

MA: $9.49▼

$10.96

52-Week Range

$2.78

Now: $8.33▼

$11.99

Volume156,600 shs

Average Volume88,675 shs

Market Capitalization$175.01 million

P/E RatioN/A

Dividend YieldN/A

Beta0.5

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix that consists of proprietary subcutaneous formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients outside of the acute care setting. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. to incorporate SmartDose drug delivery system with Furoscix. The company was founded in 2013 and is headquartered in Burlington, Massachusetts.

Beat the Market (BTM) Rank^™

3.3 Analyst's Opinion

Consensus Rating
Scpharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $12.50, Scpharmaceuticals has a potential upside of 50.1% from its current price of $8.33.
Amount of Analyst Coverage
Scpharmaceuticals has only been the subject of 2 research reports in the past 90 days.

2.5 Community Rank

Outperform Votes
Scpharmaceuticals has received 138 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Scpharmaceuticals has received 143 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Scpharmaceuticals has received 50.89% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Scpharmaceuticals and other stocks. Vote “Outperform” if you believe SCPH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SCPH will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Scpharmaceuticals does not currently pay a dividend.
Dividend Growth
Scpharmaceuticals does not have a long track record of dividend growth.

4.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Scpharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $4,999,994.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 4.07% of the stock of Scpharmaceuticals is held by insiders.
Percentage Held by Institutions
59.44% of the stock of Scpharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Scpharmaceuticals are expected to decrease in the coming year, from ($1.80) to ($1.95) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Scpharmaceuticals is -5.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Scpharmaceuticals is -5.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Scpharmaceuticals has a P/B Ratio of 3.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.95 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:SCPH

Previous Symbol

CUSIPN/A

CIK1604950

Webwww.scpharma.com

Phone617-517-0730

Debt

Debt-to-Equity Ratio0.36

Current Ratio16.96

Quick Ratio16.96

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$2.76 per share

Price / Book3.02

Profitability

EPS (Most Recent Fiscal Year)($1.77)

Net Income$-33,000,000.00

Net MarginsN/A

Return on Equity-55.07%

Return on Assets-38.27%

Miscellaneous

Employees21

Outstanding Shares21,010,000

Market Cap$175.01 million

Next Earnings Date8/5/2020 (Estimated)

OptionableNot Optionable

Receive SCPH News and Ratings via Email

Sign-up to receive the latest news and ratings for SCPH and its competitors with MarketBeat's FREE daily newsletter.

Scpharmaceuticals (NASDAQ:SCPH) Frequently Asked Questions

How has Scpharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Scpharmaceuticals' stock was trading at $7.77 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SCPH stock has increased by 7.2% and is now trading at $8.33. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Scpharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Scpharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Scpharmaceuticals.

When is Scpharmaceuticals' next earnings date?

Scpharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Scpharmaceuticals.

How were Scpharmaceuticals' earnings last quarter?

Scpharmaceuticals Inc (NASDAQ:SCPH) issued its quarterly earnings results on Tuesday, May, 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.54) by $0.19. View Scpharmaceuticals' earnings history.

What price target have analysts set for SCPH?

2 Wall Street analysts have issued 1-year target prices for Scpharmaceuticals' shares. Their forecasts range from $10.00 to $15.00. On average, they anticipate Scpharmaceuticals' share price to reach $12.50 in the next year. This suggests a possible upside of 50.1% from the stock's current price. View analysts' price targets for Scpharmaceuticals.

Has Scpharmaceuticals been receiving favorable news coverage?

Media coverage about SCPH stock has been trending extremely negative recently, InfoTrie reports. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Scpharmaceuticals earned a media sentiment score of -5.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutScpharmaceuticals.

Are investors shorting Scpharmaceuticals?

Scpharmaceuticals saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 17,400 shares, an increase of 29.9% from the April 30th total of 13,400 shares. Based on an average trading volume of 81,700 shares, the short-interest ratio is currently 0.2 days. Currently, 0.1% of the shares of the stock are short sold. View Scpharmaceuticals' Current Options Chain.

Who are some of Scpharmaceuticals' key competitors?

Some companies that are related to Scpharmaceuticals include Retrophin (RTRX), Kala Pharmaceuticals (KALA), Ardelyx (ARDX), Provention Bio (PRVB), Homology Medicines (FIXX), G1 Therapeutics (GTHX), Vanda Pharmaceuticals (VNDA), Assembly Biosciences (ASMB), Morphic (MORF), ZIOPHARM Oncology (ZIOP), DiaMedica Therapeutics (DMCAF), Stemline Therapeutics (STML), Trillium Therapeutics (TRIL), Radius Health (RDUS) and Syndax Pharmaceuticals (SNDX). View all competitors.

What other stocks do shareholders of Scpharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Scpharmaceuticals investors own include Adamas Pharmaceuticals (ADMS), Selecta Biosciences (SELB), Crispr Therapeutics (CRSP), Protalix Biotherapeutics (PLX), TG Therapeutics (TGTX), Clearside Biomedical (CLSD), Exelixis (EXEL), Fate Therapeutics (FATE), ImmunoGen (IMGN) and Melinta Therapeutics (MLNT).

Who are Scpharmaceuticals' key executives?

Scpharmaceuticals' management team includes the following people:

Mr. John H. Tucker, Pres, CEO, CFO & Director (Age 56)
Dr. Pieter Muntendam, Consultant (Age 61)
Ms. Rachael Nokes, Principal Accounting Officer
Katherine Taudvin, Director of Corp. Devel. & Investor Relations
Dr. John Mohr Pharm.D., Sr. VP of Clinical Devel. & Medical Affairs

When did Scpharmaceuticals IPO?

(SCPH) raised $96 million in an initial public offering on Friday, November 17th 2017. The company issued 6,400,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

What is Scpharmaceuticals' stock symbol?

Scpharmaceuticals trades on the NASDAQ under the ticker symbol "SCPH."

Who are Scpharmaceuticals' major shareholders?

Scpharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include RA Capital Management L.P. (16.75%), Ikarian Capital LLC (5.12%), Alambic Investment Management L.P. (0.20%), JPMorgan Chase & Co. (0.20%), Morgan Stanley (0.19%) and Matisse Capital (0.13%). Company insiders that own Scpharmaceuticals stock include Andrew J Schwab, John H Tucker, Ra Capital Healthcare Fund Lp and Ra Capital Management, LP. View institutional ownership trends for Scpharmaceuticals.

Which major investors are selling Scpharmaceuticals stock?

SCPH stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, Alambic Investment Management L.P., and Morgan Stanley. View insider buying and selling activity for Scpharmaceuticals.

Which major investors are buying Scpharmaceuticals stock?

SCPH stock was acquired by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, RA Capital Management L.P., Trexquant Investment LP, Matisse Capital, JPMorgan Chase & Co., and Acadian Asset Management LLC. Company insiders that have bought Scpharmaceuticals stock in the last two years include Andrew J Schwab, John H Tucker, Ra Capital Healthcare Fund Lp, and Ra Capital Management, LP. View insider buying and selling activity for Scpharmaceuticals.

How do I buy shares of Scpharmaceuticals?

Shares of SCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Scpharmaceuticals' stock price today?

One share of SCPH stock can currently be purchased for approximately $8.33.

How big of a company is Scpharmaceuticals?

Scpharmaceuticals has a market capitalization of $175.01 million. The company earns $-33,000,000.00 in net income (profit) each year or ($1.77) on an earnings per share basis. Scpharmaceuticals employs 21 workers across the globe.

What is Scpharmaceuticals' official website?

The official website for Scpharmaceuticals is www.scpharma.com.

How can I contact Scpharmaceuticals?

Scpharmaceuticals' mailing address is 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA, 01830. The company can be reached via phone at 617-517-0730 or via email at [email protected]

This page was last updated on 6/1/2020 by MarketBeat.com Staff